C.M. Bidwell & Associates’s Indivior Pharmaceuticals INDV Stock Holding History

C.M. Bidwell & Associates’s Portfolio INDV Stock Details INDV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$77.8K	Buy	+1,895	New	+$68.7K	0.03%	197

Other funds holding INDV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

OCM

Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

C.M. Bidwell & Associates's INDV Position: Q2 2026 in Review

C.M. Bidwell & Associates opened a new position in Indivior Pharmaceuticals (INDV) in Q2 2026: 1,895 shares worth $77.8K. The stake represents 0.03% of the portfolio and ranks #197 among its holdings.

336 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

C.M. Bidwell & Associates held 1,895 shares of Indivior Pharmaceuticals worth $77.8K as of Q2 2026.
Indivior Pharmaceuticals was a new C.M. Bidwell & Associates position in Q2 2026.
Indivior Pharmaceuticals made up 0.03% of C.M. Bidwell & Associates's portfolio in Q2 2026, its #197 holding.
336 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on C.M. Bidwell & Associates's 13F filing for Q2 2026, filed 11 Aug 2026.